Supplementary Table S2 from Pembrolizumab and Cabozantinib in Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Long-term Survival Update with a Biomarker Analysis
Nabil F. Saba(Emory University), Christine H. Chung(Moffitt Cancer Center), Dong M. Shin(Emory University), Mihir R. Patel(Emory University), Yuan Liu(Emory University), William A. Stokes(Emory University), Jennifer H. Gross(Emory University), Kedar Kirtane(Moffitt Cancer Center), Asari Ekpenyong(Emory University), Nicole C. Schmitt(Emory University), James E. Bates(The University of Texas MD Anderson Cancer Center), Jill Remick(Emory University), Ritu Chaudhary(Moffitt Cancer Center), Soumon Rudra(Emory University), Angelo Marra(Emory University), Yong Teng(Emory University), Conor Steuer(Emory University), Mark W. McDonald(Emory University), Ashley A. McCook‐Veal(Emory University), Xiaofei Song(Jiangsu University), Robbert J.C. Slebos(University of Iowa)
Cited by 0
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Proteogenomic characterization of human colon and rectal cancer
|Nature|2014|1.6k
Is It Time to Start Transitioning From 2D to 3D Cell Culture?
|Frontiers in Molecular Biosciences|2020|1.6k